Muggia F M, Blum R H, Wernz J C
Cancer Treat Rep. 1981;65 Suppl 4:35-7.
Future studies with daunorubicin involve mainly comparative evaluations with other anthracycline antibiotics and related compounds. Efforts are ongoing to improve the therapeutic index of these drugs. This includes not only laboratory development but also clinical evaluation of analogs, manipulations in dose schedules, and the use of protectors of toxic manifestations, primarily of cardiomyopathy. Technological advances in the clinical area permit, for example, the exploration of daunorubicin and related compounds by continuous infusion under more precise pharmacologic and cardiologic monitoring than was possible when they were initially introduced.
未来关于柔红霉素的研究主要涉及与其他蒽环类抗生素及相关化合物的比较评估。目前正在努力提高这些药物的治疗指数。这不仅包括实验室研发，还包括类似物的临床评估、剂量方案的调整以及毒性表现（主要是心肌病）保护剂的使用。临床领域的技术进步使得例如在比最初引入柔红霉素及其相关化合物时更精确的药理和心脏监测下通过持续输注来研究它们成为可能。
